The American Society of Clinical Oncology (ASCO) held its 51st annual meeting on May 29th – June 2, 2015 in Chicago, Illinois.
The ASCO meeting brought together over 30,000 oncology professionals from more than 100 countries from around the world. During the course of five days, there were a series of educational sessions from world-renowned faculty addressing trending topics in the field of oncology, including targeted therapy, state-of-the-art treatment modalities, and new therapies.
Particularly, the science sessions presented the latest revolutionary cancer research in oral and poster format. Exactly 4,882 abstracts were published and 2,392 were presented onsite in Chicago in Oral Abstract Session, Poster Discussion Sessions, and Poster Sessions. In addition, esteemed faculty presented in the education sessions in 17 tracks, including five cross-cutting tracks: clinical trials, ethics, geriatric oncology, international, and value.
Among the many groundbreaking discoveries presented at ASCO, one that I found particularly interesting is the announcement of a new oncology trial starting in July. In this clinical trial, researchers will disregard the type of cancer and instead will focus on the gene sequence. Traditionally patients get treated based on the type of cancer. However, in this new study, patients will have their tumor genes sequenced in order to determine what drugs will be administered. Patients with various cancers will be treated with the same treatment.
New technology is now allowing researchers to measure the genes that are abnormal in a given tumor and try to find the drug that will target the abnormality. The benefits of this approach are to hopefully increase efficacy while reducing toxicity of the side effects associated with chemotherapy.
For a full list of other ASCO highlights please visit http://am.asco.org/. ASCO will return to Chicago, on June 3-7, 2016.